Grant: Canadian Lung Association Research Studentship
University of Manitoba
$12,000.00
Multidimensional role of CD38 in oxidised phosphatidylcholine (OxPCs) induce obstructive lung diseases
EF 2022-23
Résumé
We are not only the first who identified but also characterized the OxPCs species in the human lungs which are the persistent candidate of oxidative stress in lung pathophysiology. Further, based on our expertise and profound lung (patho)biology experience we have identified a possible target protein called CD38, may have a critical role in severity of the disease. Thus, this project will identify whether CD38 is a molecular switch that promotes the adverse effects of OxPCs in asthma pathogenesis.
In Canada, over 3.8 million individuals suffer with asthma, including nearly 12% of children. Asthma remains the number one reason for children to present at emergency room each year across Canada. Obstructive lung diseases such as asthma are driven by persistent oxidative stress that damages tissue and promotes accelerated aging. Allergic and air pollution exposures, and microbial and viral infection lead to lung inflammation and oxidative stress. Unfortunately, first line asthma therapies do not specifically mitigate oxidative stress. This permits oxidation-associated changes in cellular components such as proteins and lipids in all cells, and create biologically active molecules that promote disease which leads to high mortality rate.
Project is designed to identify the molecular links and mechanism involve in oxidative stress associated asthma pathogenesis. We have focused on phospholipids, specifically oxidized phosphatidylcholine (OxPCs), in the lung. OxPCs are central pathological triggers in many chronic diseases. As we have led discovery of OxPCs in the lungs of human asthmatics, we are now trying to uncover the molecular pathways for OxPCs-induced asthma pathogenesis. This will be critical to identify new therapeutics that do target the effects of oxidative stress in asthma.
I will use cultured human ASM cells from healthy and asthmatic donors, as well as mouse models of allergic (house dust mite) asthma to decipher the role of CD38 in OxPCs-associated pathobiology. Critical indices I will assess include OxPCs induced structural changes in the airways, associated with extracellular matrix (ECM) expression. Please refer to two page proposed research plan for more details.
By defining molecular mechanisms involving CD38 that elucidate the effects of OxPCs on airway inflammation, [Ca++]i signaling, ECM production and airway remodeling my research will open a new potential avenues to develop management approaches for asthma pathogenesis. It will enhance the scientific understanding in context of role of persistence oxidative stress in asthma and therapeutic consideration from the clinical point of view. Overall, it will improve not only the disease management but also a potential asthma therapy outcome.
Programme
Canadian Lung Association Research Studentship
Bénéficiaire
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
476986
Name
Pandey Dheerendra K
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Lung Association (Ottawa)
Prcname2
Special Cases
Projecttitle
Multidimensional role of CD38 in oxidised phosphatidylcholine (OxPCs) induce obstructive lung diseases
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$12,000
Cihrequipment2
$0
Programname2
Canadian Lung Association Research Studentship
Keyworddelim
Airways Hyperresponsiveness; Asthma; Cd38; Oxidized Phospholipids; Reactive Oxygen Species (Ros)
Abstract
We are not only the first who identified but also characterized the OxPCs species in the human lungs which are the persistent candidate of oxidative stress in lung pathophysiology. Further, based on our expertise and profound lung (patho)biology experience we have identified a possible target protein called CD38, may have a critical role in severity of the disease. Thus, this project will identify whether CD38 is a molecular switch that promotes the adverse effects of OxPCs in asthma pathogenesis.
In Canada, over 3.8 million individuals suffer with asthma, including nearly 12% of children. Asthma remains the number one reason for children to present at emergency room each year across Canada. Obstructive lung diseases such as asthma are driven by persistent oxidative stress that damages tissue and promotes accelerated aging. Allergic and air pollution exposures, and microbial and viral infection lead to lung inflammation and oxidative stress. Unfortunately, first line asthma therapies do not specifically mitigate oxidative stress. This permits oxidation-associated changes in cellular components such as proteins and lipids in all cells, and create biologically active molecules that promote disease which leads to high mortality rate.
Project is designed to identify the molecular links and mechanism involve in oxidative stress associated asthma pathogenesis. We have focused on phospholipids, specifically oxidized phosphatidylcholine (OxPCs), in the lung. OxPCs are central pathological triggers in many chronic diseases. As we have led discovery of OxPCs in the lungs of human asthmatics, we are now trying to uncover the molecular pathways for OxPCs-induced asthma pathogenesis. This will be critical to identify new therapeutics that do target the effects of oxidative stress in asthma.
I will use cultured human ASM cells from healthy and asthmatic donors, as well as mouse models of allergic (house dust mite) asthma to decipher the role of CD38 in OxPCs-associated pathobiology. Critical indices I will assess include OxPCs induced structural changes in the airways, associated with extracellular matrix (ECM) expression. Please refer to two page proposed research plan for more details.
By defining molecular mechanisms involving CD38 that elucidate the effects of OxPCs on airway inflammation, [Ca++]i signaling, ECM production and airway remodeling my research will open a new potential avenues to develop management approaches for asthma pathogenesis. It will enhance the scientific understanding in context of role of persistence oxidative stress in asthma and therapeutic consideration from the clinical point of view. Overall, it will improve not only the disease management but also a potential asthma therapy outcome.
Competitiondate
202210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pandey, Dheerendra K
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Circ &Respiratory Hlth~ $12,000~ $0~